Business
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within A
About this update from Sutro Biopharma, Inc.
[{"type":"image","alt":"Sutro Biopharma, Inc.","displaySize":"","headline":null,"caption":"Sutro Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":186,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rd31Oc6_ZbJywDRY5HheFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8","width":186,"height":55}},"lazy":false},{"type":"text","content":"- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -","length":132,"tagName":"p"},{"type":"text","content":"- Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively -","length":144,"tagName":"p"},{"type":"text","content":"- Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 -","length":162,"tagName":"p"},{"type":"text","content":"- IND-enabling toxicology study ongoing for one program within Astellas iADC collaboration, triggering $7.5 million milestone payment to Sutro -","length":144,"tagName":"p"},{"type":"text","content":"- Cash, cash equivalents and marketable securities as of March 31, 2025 of $249.0 million, with cash runway expected into early 2027, excluding additional anticipated milestones from existing collaborations -","length":208,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2025 and recent business highlights.","length":316,"tagName":"p"},{"type":"text","content":"“In the first quarter, we announced a strategic decision to shift Sutro’s product candidate focus from luvelta to our pipeline of wholly-owned novel exatecan and dual-payload ADCs. As part of this review, we selected STRO-004—a next-generation Tissue Factor-targeting exatecan/Topo 1 ADC—as our lead clinical candidate, supported by strong preclinical data that point to its best-in-class potenti...